Janssen secures EC approval for preventive Ebola vaccine
The Ebola vaccine regimen has been developed by leveraging Janssen’s AdVac technology, and Bavarian Nordic’s MVA-BN technology
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
02 Jul 20
The Ebola vaccine regimen has been developed by leveraging Janssen’s AdVac technology, and Bavarian Nordic’s MVA-BN technology
01 Jul 20
BAVENCIO is a human anti-programmed death ligand-1 (PD-L1) antibody, co-developed and co-commercialised by Pfizer and EMD Serono
30 Jun 20
Duvroq has been designed to provide an orally-convenient treatment option, avoid administration challenges and need for cold storage…
30 Jun 20
Phesgo offers faster administration of Perjeta and Herceptin under the skin in just minutes, compared to hours with…
29 Jun 20
Reblozyl is an erythroid maturation agent that regulates late-stage red blood cell (RBC) maturation to reduce or prevent…
26 Jun 20
Novartis, along with certain of its subsidiaries, has agreed to pay $233.9m to the DOJ and $112.8m to…
26 Jun 20
The European Medicines Agency has accepted the company’s application for review of the marketing authorisation of imlifidase in…
25 Jun 20
KEYTRUDA is an anti PD-1 therapy that works by enhancing the body’s immune system to detect and fight…
23 Jun 20
The regulatory authorisation indicated Qinlock for the treatment of advanced gastrointestinal stromal tumour in adult patients who received…
22 Jun 20
CDSCO granted restricted emergency use of Favipiravir tablets to Glenmark Pharmaceuticals; and Remdesivir injectable formulations to Cipla and…